Amarin Corporation PLC

Amarin Corporation PLC

  • Price (USD)4.95
  • Today's Change-0.09 / -1.79%
  • Shares traded100.00
  • 1 Year change-26.34%
  • Beta2.2831
Data delayed at least 15 minutes, as of Apr 20 2021 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

  • Revenue in USD (TTM)614.06m
  • Net income in USD-18.00m
  • Incorporated1989
  • Employees1.00k
  • Location
    Amarin Corporation PLCGemini House, Bartholomews WalkDUBLIN FK7 9JQIrelandIRL
  • Phone+353 16699020
  • Websitehttp://www.amarincorp.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Sundial Growers Inc48.32m-163.45m1.83bn394.00--3.68--37.96-0.9523-1.170.19790.2290.15141.002.80122,641.60-51.26---82.14--15.07---338.68--3.70-3.990.0053---4.16---44.57------
Kura Oncology Inc0.00-89.63m1.85bn88.00--3.03-----1.69-1.690.009.230.00----0.00-20.16-28.85-21.15-30.79------------0.0117-------41.95--102.35--
IGM Biosciences Inc0.00-81.36m1.86bn107.00--4.86-----2.64-2.640.0011.940.00----0.00-24.29---25.27--------------0.00-------88.61------
bluebird bio Inc250.73m-618.70m1.87bn1.21k--1.37--7.46-9.95-9.954.0320.400.1429--626.84206,705.70-35.27-31.85-40.16-34.5897.85---246.75-681.64----0.00--461.2577.8821.65--32.66--
Axsome Therapeutics Inc0.00-102.90m1.89bn60.00--16.63-----2.77-2.770.003.040.00----0.00-50.60-60.46-57.37-71.84-----------38.640.2981-------50.56--17.83--
Revance Therapeutics Inc15.33m-282.09m1.91bn470.00--4.95--124.83-4.85-4.850.26425.410.0289--16.7632,606.38-53.20-50.74-58.86-56.1268.50---1,840.71-3,963.977.29-24.930.3254--3,610.65119.61-76.94--4.84--
Morphic Holding Inc44.95m-45.00m1.93bn89.00--11.97--42.90-1.48-1.481.454.530.1835--8.34505,000.00-18.37---21.68-------100.12------0.00--164.74---3.86------
Amarin Corporation plc (ADR)614.06m-18.00m1.95bn1.00k--3.10--3.17-0.0507-0.05071.591.600.66450.98974.53614,060.00-1.95-14.03-2.77-21.6678.5977.19-2.93-19.182.25--0.00--42.8949.6720.51--55.18--
Jufeel International Group19.35m6.62m1.95bn144.00----260.34100.760.23620.23620.69041.170.40341.7724.22134,392.9014.07--22.24--77.98--34.87--0.114--0.0249---36.72---56.36------
BioCryst Pharmaceuticals, Inc.17.81m-182.81m1.97bn246.00------110.81-1.09-1.090.1065-0.10890.06990.47621.1672,406.51-71.69-62.76-117.19-115.7990.5992.33-1,026.35-370.133.00-28.901.08---63.53-18.07-67.88---36.86--
NGM Biopharmaceuticals Inc87.37m-102.49m1.98bn210.00--6.50--22.64-1.49-1.491.283.970.2463--15.01416,038.10-28.89---32.68-------117.31------0.00---15.62---139.48------
China Zhong Qi Holdings Ltd1.19m820.58k2.00bn3.000.01641.36--1,687.0460.9760.9788.080.733914.21--185.24--983.85-117.92----79.4878.1069.22-122.76----0.00--1,568.2732.30172.76------
MacroGenics Inc104.88m-129.74m2.02bn370.00--6.40--19.25-2.55-2.552.005.260.3035--5.86283,467.60-37.54-31.27-43.58-35.91-----123.70-110.93----0.00--63.400.786514.54---8.48--
Madrigal Pharmaceuticals Inc0.00-202.24m2.02bn42.00--8.16-----13.09-13.090.0015.470.00----0.00-55.48-28.86-61.53-31.16------------0.00-------140.92------
CytoDyn Inc0.00-159.18m2.04bn19.00---------0.3137-0.31370.00-0.01110.00----0.00-196.90-375.22-1,959.47----------0.2741-3.051.15-------121.41--17.20--
Myriad Genetics, Inc.557.00m-244.40m2.05bn2.70k--2.28--3.68-3.27-3.007.4611.680.37176.465.36206,296.30-16.32---17.86--68.01---43.90--2.48-20.800.2033--------------
Data as of Apr 20 2021. Currency figures normalised to Amarin Corporation PLC's reporting currency: US Dollar USD

Institutional shareholders

23.14%Per cent of shares held by top holders
HolderShares% Held
Baker Bros. Advisors LPas of 31 Dec 202027.99m7.11%
Eversept Partners LPas of 31 Dec 202015.94m4.05%
BVF Partners LPas of 31 Dec 202010.76m2.73%
Tavistock Life Sciences Co. (Investment Management)as of 31 Dec 20206.00m1.52%
Avoro Capital Advisor LLCas of 31 Dec 20206.00m1.52%
Grosvenor Capital Management LPas of 31 Dec 20205.89m1.50%
SCP Investment LPas of 31 Dec 20205.50m1.40%
ClearBridge Investments LLCas of 31 Dec 20204.63m1.18%
Rock Springs Capital Management LPas of 31 Dec 20204.20m1.07%
Morgan Stanley & Co. LLCas of 31 Dec 20204.18m1.06%
More ▼
Data from 31 Dec 2020 - 31 Dec 2020Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.